By a News Reporter-Staff News Editor at Diabetes Week -- Research findings on Nanoparticles are discussed in a new report. According to news reporting originating from Jiangsu, People's Republic of China, by NewsRx correspondents, research stated, "Noninvasive assessment of pancreatic -cell mass would tremendously aid in managing type 1 diabetes (T1D). Toward this goal, we synthesized an exendin-4 conjugated magnetic iron oxide-based nanoparticle probe targeting glucagon-like peptide 1 receptor (GLP-1R), which is highly expressed on the surface of pancreatic -cells."
Our news editors obtained a quote from the research from China Pharmaceutical University, "In vitro studies in TC-6, the -cell line, showed specific accumulation of the targeted probe (termed MN-Ex10-Cy5.5) compared with nontargeted (termed MN-Cy5.5). In vivo magnetic resonance imaging showed a significant transverse relaxation time (T2) shortening in the pancreata of mice injected with the MN-Ex10-Cy5.5 probe compared with control animals injected with the nontargeted probe at 7.5 and 24 h after injection. Furthermore, T2 of the pancreata of prediabetic NOD mice was significantly higher than that of diabetic NOD mice after the injection of MN-Ex10-Cy5.5, indicating the decrease of probe accumulation in these animals due to -cell loss. Of note, T2 of prediabetic and diabetic NOD mice injected with MN-Cy5.5 was not significantly changed, reflecting the nonspecific mode of accumulation of nontargeted probe."
According to the news editors, the research concluded: "We believe our results point to the potential for using this agent for monitoring the disease development and response of T1D to therapy."
For more information on this research see: GLP-1R-Targeting Magnetic Nanoparticles for Pancreatic Islet Imaging. Diabetes, 2014;63(5):1465-1474. Diabetes can be contacted at: Amer Diabetes Assoc, 1701 N Beauregard St, Alexandria, VA 22311-1717, USA. (Elsevier - www.elsevier.com; Diabetes - www.elsevier.com/wps/product/cws_home/707821)
The news editors report that additional information may be obtained by contacting P. Wang, China Pharmaceutical University, Sch Pharm, Center Drug Discovery, Nanjing, Jiangsu, People's Republic of China. Additional authors for this research include B. Yoo, J.S. Yang, X.L. Zhang, A. Ross, P. Pantazopoulos, G.P. Dai and A. Moore (see also Nanoparticles).
Keywords for this news article include: Asia, Jiangsu, Pancreas, Nanotechnology, Gastroenterology, Emerging Technologies, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC